Goldline Pharmaceutical promoter raises stake to 29.27% with open market buy
- Promoter Amol Laxmikant Mujumdar acquired 60,000 shares via open market
- Stake increased by 0.62% to reach 29.27% of paid-up capital
- Total issued share capital remains unchanged at 9.6 million shares
- No encumbrances or pledges reported on the promoter's holdings
*this image is generated using AI for illustrative purposes only.
Goldline Pharmaceutical promoter and managing director Amol Laxmikant Mujumdar increased his holding in the company by acquiring 60,000 equity shares through an open market purchase on August 31, 2026.
The transaction brings the promoter’s total shareholding to 2,809,988 shares, representing a 29.27% stake in the company’s paid-up capital. Prior to this acquisition, Mujumdar held 2,749,988 shares, accounting for 28.64% of the voting rights.
Acquisition Details
The purchase was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The details of the transaction are as follows:
| Metric | Value |
|---|---|
| Date of acquisition | August 31, 2026 |
| Shares acquired | 60,000 |
| Mode of acquisition | Open market purchase |
| Stake increase | 0.62% |
| Total post-acquisition stake | 29.27% |
The company’s total issued and paid-up share capital remains unchanged at 9,600,000 equity shares following the transaction. No warrants, convertible securities, or other instruments entitling the acquirer to receive shares were involved in the deal.
What the Numbers Show
The open market purchase indicates a direct increase in promoter confidence without diluting existing shareholders, as the total equity capital remains static at 9.6 million shares. The absence of any encumbrances or pledges on the newly acquired or existing shares suggests a clean balance sheet position for the promoter group regarding these holdings.
Historical Stock Returns for Goldline Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.01% | 0.0% | -19.45% | -41.87% | -41.87% | -41.87% |
How might this increase in promoter holding influence Goldline Pharmaceutical's stock price volatility and investor sentiment in the coming quarter?
Does this open market purchase signal upcoming strategic initiatives or operational milestones that the management expects to drive value?
What is the current liquidity profile of Goldline Pharmaceutical's shares, and could sustained buying by the promoter lead to a significant premium over fair value?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
